-
T-cell and antibody responses in immunocompromised patients with hematologic malignancies indicate strong potential of SARS-CoV-2 mRNA vaccines
Pothast, C. R., Hofsink, Q., Haggenburg, S., Dijkland, R. C., van de Meent, M., van Dijk, K., Bhoekhan, M. S., Haverkate, N. J. E., van Meerloo, J., Falkenburg, J. H. F., de Groen, R. A. L., Broers, A. E. C., van Doesum, J. A., van Binnendijk, R. S., den Hartog, G., Lissenberg-Witte, B. I., Kater, A. P., Smits, G. P., Wouters, D. & van Leeuwen, E. M. M. & 13 others, , 1 Nov 2025, In: Haematologica. 110, 11, p. 2799-2805 7 p.Research output: Contribution to journal › Article › Academic › peer-review
-
COVID-19 vaccine immunogenicity and population-based outcome studies in patients with hematologic malignancies
Hofsink, Q., 2025, 230 p.Research output: PhD thesis › Research HvA, graduation HvA (not in use)
-
Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study
COBRA KAI Study Team, 1 Jul 2023, In: EClinicalMedicine. 61, 102040.Research output: Contribution to journal › Article › Academic › peer-review
- All publications
